lamotrigine has been researched along with Exanthem in 66 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lamotrigine is a novel anticonvulsant agent that has recently been introduced as a long-term treatment in bipolar disorder." | 8.82 | Lamotrigine in the treatment of bipolar disorder. ( Bhagwagar, Z; Goodwin, GM, 2005) |
| "To provide a qualitative, systematic update and review of the pharmacology, pharmacokinetics, efficacy in mood disorders, adverse effects, and costs of lamotrigine." | 8.81 | Lamotrigine update and its use in mood disorders. ( Hurley, SC, 2002) |
| "Although lamotrigine may be useful for treating patients with treatment-resistant bipolar disorder, some lamotrigine-associated adverse effects, including mild to moderate skin rash, may prevent the continuation of treatment." | 7.88 | Lamotrigine Rechallenge in Treatment-Resistant Bipolar Disorder. ( Inaba, T; Kato, TA; Kunitake, Y; Mizoguchi, Y; Monji, A; Sogawa, R; Tateishi, H, 2018) |
| " We herein present an unusual case of DRESS syndrome due to lamotrigine with reactivation of Epstein-Barr virus, which developed autoimmune LE and syndrome of inappropriate antidiuretic hormone secretion." | 7.83 | Autoimmune Limbic Encephalitis and Syndrome of Inappropriate Antidiuretic Hormone Secretion Associated with Lamotrigine-induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) Syndrome. ( Ozisik, L; Saka, E; Tanriover, MD, 2016) |
| "Lamotrigine (LTG) has a good efficacy and tolerability as initial monotherapy for patients with newly diagnosed epilepsy (NDE)." | 7.79 | Depression in patients with newly diagnosed epilepsy predicts lamotrigine-induced rash: a short-term observational study. ( Park, SP, 2013) |
| "This is the first reported case of lamotrigine-induced DRESS syndrome with pancreatitis as the initial visceral involvement." | 7.76 | First report of lamotrigine-induced drug rash with eosinophilia and systemic symptoms syndrome with pancreatitis. ( Augusto, JF; Croue, A; Dib, N; Lerolle, N; Mercat, A; Peres, M; Roquin, G, 2010) |
| "To examine the safety of lamotrigine (LTG) used in general practice to treat epilepsy." | 7.69 | Safety of long-term lamotrigine in epilepsy. ( Freemantle, SN; Mackay, FJ; Mann, RD; Pearce, GL; Wilton, LV, 1997) |
| " Partly because of these properties, frequent dosing adjustments are generally unnecessary, and therapeutic monitoring is not required under most circumstances." | 6.43 | Pharmacokinetics, toxicology and safety of lamotrigine in epilepsy. ( Biton, V, 2006) |
| "Angioedema has been reported with the use of oxcarbazepine and carbamazepine." | 5.38 | Levetiracetam induced angioedema in a patient with previous anticonvulsant hypersensitivity reaction to phenytoin and lamotrigine. ( Alkhotani, A; McLachlan, RS, 2012) |
| "We assessed rash incidence in 100 patients with DSM-IV bipolar disorder instructed, for their first 3 months taking lamotrigine, to avoid other new medicines and new foods, cosmetics, conditioners, deodorants, detergents, and fabric softeners, as well as sunburn and exposure to poison ivy/oak." | 5.11 | Dermatology precautions and slower titration yield low incidence of lamotrigine treatment-emergent rash. ( Alarcon, AM; Becker, OV; Chandler, RA; Ketter, TA; Nowakowska, C; O'Keeffe, CM; Schumacher, MR; Wang, PW, 2005) |
| "Lamotrigine is a novel anticonvulsant agent that has recently been introduced as a long-term treatment in bipolar disorder." | 4.82 | Lamotrigine in the treatment of bipolar disorder. ( Bhagwagar, Z; Goodwin, GM, 2005) |
| "To provide a qualitative, systematic update and review of the pharmacology, pharmacokinetics, efficacy in mood disorders, adverse effects, and costs of lamotrigine." | 4.81 | Lamotrigine update and its use in mood disorders. ( Hurley, SC, 2002) |
| "We prospectively enrolled 33 adult patients (age 18-85) who were diagnosed with epilepsy and started lamotrigine administration for the first time at a single tertiary hospital." | 4.02 | A new rapid titration protocol for lamotrigine that reduces the risk of skin rash. ( Chang, H; Chu, K; Jang, Y; Jun, JS; Jung, KH; Jung, KY; Kang, HR; Kim, N; Kim, TJ; Lee, SK; Lee, ST; Moon, J; Park, KI; Shin, YW, 2021) |
| "Although lamotrigine may be useful for treating patients with treatment-resistant bipolar disorder, some lamotrigine-associated adverse effects, including mild to moderate skin rash, may prevent the continuation of treatment." | 3.88 | Lamotrigine Rechallenge in Treatment-Resistant Bipolar Disorder. ( Inaba, T; Kato, TA; Kunitake, Y; Mizoguchi, Y; Monji, A; Sogawa, R; Tateishi, H, 2018) |
| " We herein present an unusual case of DRESS syndrome due to lamotrigine with reactivation of Epstein-Barr virus, which developed autoimmune LE and syndrome of inappropriate antidiuretic hormone secretion." | 3.83 | Autoimmune Limbic Encephalitis and Syndrome of Inappropriate Antidiuretic Hormone Secretion Associated with Lamotrigine-induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) Syndrome. ( Ozisik, L; Saka, E; Tanriover, MD, 2016) |
| "Lamotrigine (LTG) has a good efficacy and tolerability as initial monotherapy for patients with newly diagnosed epilepsy (NDE)." | 3.79 | Depression in patients with newly diagnosed epilepsy predicts lamotrigine-induced rash: a short-term observational study. ( Park, SP, 2013) |
| " All had dermatological manifestations, eosinophilia and systemic (haematological and hepatic) manifestations that could be attributed to treatment with aromatic AEDs (carbamazepine, 2 patients; lamotrigine, 3 patients; phenytoin, 3 patients)." | 3.77 | Risk factors associated with DRESS syndrome produced by aromatic and non-aromatic antipiletic drugs. ( Kochen, S; Pereira de Silva, N; Piquioni, P; Saidon, P, 2011) |
| "This is the first reported case of lamotrigine-induced DRESS syndrome with pancreatitis as the initial visceral involvement." | 3.76 | First report of lamotrigine-induced drug rash with eosinophilia and systemic symptoms syndrome with pancreatitis. ( Augusto, JF; Croue, A; Dib, N; Lerolle, N; Mercat, A; Peres, M; Roquin, G, 2010) |
| "We describe an 11-year-old girl with a seizure disorder who developed fever, rash, rhabdomyolysis, and multiorgan failure 2 weeks after commencing a transition from sodium valproate to lamotrigine therapy." | 3.75 | Life-threatening organ failure after lamotrigine therapy. ( Dargan, PI; Ferguson, LP; Hood, JL; Tibby, SM, 2009) |
| " We present a 12 years old female who was a known case of idiopathic generalized tonic-clonic convulsion and presented with fever, diarrhea and generalized erythematous eruption after 2 weeks of being under treatment with maintenance doses of Lamotrigine (LTG) and Valproate (VPA)." | 3.74 | Intravenous immunoglobulin in the treatment of lamotrigine- induced toxic epidermal necrolysis. ( Inaloo, S; Serati Shirazi, Z, 2008) |
| "This report describes the laboratory and physical manifestations of lamotrigine-like toxicity in a young man with refractory epilepsy receiving lamotrigine presenting as anticonvulsant hypersensitivity syndrome (AHS) associated with an abrupt change of drug product." | 3.74 | Progressive anticonvulsant hypersensitivity syndrome associated with change of drug product. ( Sabers, A; Sabroe, TP, 2008) |
| "To examine the safety of lamotrigine (LTG) used in general practice to treat epilepsy." | 3.69 | Safety of long-term lamotrigine in epilepsy. ( Freemantle, SN; Mackay, FJ; Mann, RD; Pearce, GL; Wilton, LV, 1997) |
| "Lamotrigine was added to the current therapy regime for DSM-IV bipolar I patients on an open-label basis for 12 weeks." | 2.74 | Rash in adult patients receiving lamotrigine to treat bipolar I disorder in Korea: a multicenter, prospective, naturalistic, open-label trial. ( Ahn, YM; Bahk, WM; Chung, SK; Jon, DI; Joo, YH; Jung, SH; Kim, W; Kim, Y; Lee, YS; Min, KJ; Seo, JS; Seok, JH; Shin, YC; Won, SH; Woo, YS; Yoon, BH, 2009) |
| "Carbamazepine or phenytoin was withdrawn over the next 4 weeks; then patients entered a 12-week monotherapy period." | 2.69 | An active-control trial of lamotrigine monotherapy for partial seizures. ( Chang, GY; Gilliam, F; Messenheimer, J; Nyberg, J; Risner, ME; Rudd, GD; Sackellares, JC; Vazquez, B, 1998) |
| "Rash was the most commonly reported AE, occurring in 7." | 2.52 | Safety of lamotrigine in paediatrics: a systematic review. ( Choonara, I; Egunsola, O; Sammons, HM, 2015) |
| "The overall incidence of skin rash with LTG therapy was 9." | 2.52 | Risk of a lamotrigine-related skin rash: current meta-analysis and postmarketing cohort analysis. ( Huang, DH; Huang, XS; Jia, WQ; Lang, SY; Tian, CL; Wang, XQ; Xiong, J; Xu, WH; Yu, SY; Zhang, JT, 2015) |
| "Rash was the only adverse effect causing discontinuation (N = 7)." | 2.46 | Lamotrigine adjunctive therapy for refractory generalized tonic-clonic seizures. ( Leong, K; Marson, AG; Tjia-Leong, E, 2010) |
| "Lamotrigine has been shown to be useful in the long-term prophylaxis of depressive episodes in BD." | 2.45 | Lamotrigine-associated rash: to rechallenge or not to rechallenge? ( Bhagwagar, Z; Lorberg, B; Youssef, NA, 2009) |
| " Partly because of these properties, frequent dosing adjustments are generally unnecessary, and therapeutic monitoring is not required under most circumstances." | 2.43 | Pharmacokinetics, toxicology and safety of lamotrigine in epilepsy. ( Biton, V, 2006) |
| " Data from clinical trials clearly point to exceeding currently recommended dosage guidelines of lamotrigine and co-administration of valproic acid (valproate sodium) as risk factors for rash." | 2.40 | Safety review of adult clinical trial experience with lamotrigine. ( Giorgi, L; Messenheimer, J; Mullens, EL; Young, F, 1998) |
| "The mechanism of drug-induced skin rash is not well understood." | 1.91 | Potential Involvement of Sulfotransferase in the Mechanism of Lamotrigine-induced Skin Rash. ( Bairam, A; Cao, Y; Liu, MC; Uetrecht, J, 2023) |
| "Patients with DRESS syndrome typically present with rash, swelling, fever, and systemic manifestations." | 1.72 | DRUG-INDUCED HYPERSENSITIVITY SYNDROME CAUSED BY LAMOTRIGINE, A CASE REPORT. ( Ikić Matijašević, M; Nesek Adam, V; Vrhovski, D, 2022) |
| "Lithium carbonate was associated with increased risks of rash (PT), drug interaction (PT), and tubulointerstitial diseases (SMQ)." | 1.72 | Analysis of adverse drug events in patients with bipolar disorders using the Japanese Adverse Drug Event Report database. ( Nabekura, T; Uwai, Y, 2022) |
| "The diagnoses were major depressive disorder (n = 39), bipolar I disorder (n = 10), and bipolar II disorder (n = 35)." | 1.56 | A High Plasma Lamotrigine Concentration at Week 2 as a Risk Factor for Lamotrigine-Related Rash. ( Kagawa, S; Kondo, T; Mihara, K; Nagai, G; Nakamura, A; Nemoto, K; Suzuki, T, 2020) |
| " LEV has milder adverse events than OXC and LTG in clinical practice." | 1.56 | Comparison of long-term efficacy, tolerability, and safety of oxcarbazepine, lamotrigine, and levetiracetam in patients with newly diagnosed focal epilepsy: An observational study in the real world. ( Li, R; Li, Y; Ou, S; Pan, S; Wang, Y; Xia, L; Zhou, Q, 2020) |
| "Maculopapular exanthema and delayed-appearing urticaria were the most reported hypersensitivity reactions to AEDs." | 1.51 | Hypersensitivity reactions to antiepileptic drugs in children. ( Atanasković-Marković, M; Ćirković Veličković, T; Gavrović-Jankulović, M; Janković, J; Nikolić, D; Škorić, D; Tmušić, V, 2019) |
| "She was diagnosed with left frontal lobe epilepsy, and a lamotrigine regimen was initiated." | 1.40 | Seizure freedom after lamotrigine rash: a peculiar phenomenon in epilepsy. ( Iwasaki, M; Jin, K; Kakisaka, Y; Kato, K; Nakasato, N, 2014) |
| "Angioedema has been reported with the use of oxcarbazepine and carbamazepine." | 1.38 | Levetiracetam induced angioedema in a patient with previous anticonvulsant hypersensitivity reaction to phenytoin and lamotrigine. ( Alkhotani, A; McLachlan, RS, 2012) |
| "The development of a skin rash is often associated with a rapid escalation of lamotrigine dose." | 1.35 | Feasibility of a slower lamotrigine titration schedule for bipolar depression: a naturalistic study. ( Chang, JS; Ha, K; Ha, TH; Joe, SH; Rim, HD; Won, S, 2009) |
| " The dosage schedule was: 5 mg every day or every second day for 14 days, increased by 5 mg every 14th day to 25 mg a day." | 1.33 | Lamotrigine-induced rash--worth a rechallenge. ( Dam, M; P-Codrea Tigaran, S; Sidenius, P, 2005) |
| "Severe rash is rare when using the currently recommended titration rate." | 1.33 | Predictors of Lamotrigine-associated rash. ( Buchsbaum, R; Hager, M; Hirsch, LJ; Resor, SR; Spencer, HT; Straka, T; Weintraub, DB, 2006) |
| "Lamotrigine is a novel anticonvulsant initially used in epilepsy treatment." | 1.33 | The relevance of monitoring lamotrigine serum concentrations in chronic pain patients. ( Devulder, J, 2006) |
| "The lamotrigine was stopped immediately when the rash was identified and was subsequently re-introduced, using a special very-low-dose-escalation regime, starting with 0." | 1.31 | Successful re-introduction of lamotrigine after initial rash. ( Besag, FM; Ng, GY; Pool, F, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (9.09) | 18.2507 |
| 2000's | 25 (37.88) | 29.6817 |
| 2010's | 24 (36.36) | 24.3611 |
| 2020's | 11 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Abdelnabi, M | 1 |
| Elmssary, M | 1 |
| Sekhon, J | 1 |
| Benjanuwattra, J | 1 |
| Uwai, Y | 1 |
| Nabekura, T | 1 |
| Vrhovski, D | 1 |
| Ikić Matijašević, M | 1 |
| Nesek Adam, V | 1 |
| Cao, Y | 1 |
| Bairam, A | 1 |
| Liu, MC | 1 |
| Uetrecht, J | 1 |
| Tsai, LH | 1 |
| Lin, JW | 1 |
| Suzuki, T | 1 |
| Mihara, K | 1 |
| Nagai, G | 1 |
| Kagawa, S | 1 |
| Nakamura, A | 1 |
| Nemoto, K | 1 |
| Kondo, T | 1 |
| Fujii, K | 1 |
| Okayasu, H | 1 |
| Shinozaki, T | 1 |
| Shimoda, K | 1 |
| Ozeki, Y | 1 |
| Bresnahan, R | 1 |
| Panebianco, M | 1 |
| Marson, AG | 2 |
| Li, R | 1 |
| Zhou, Q | 1 |
| Ou, S | 1 |
| Wang, Y | 1 |
| Li, Y | 1 |
| Xia, L | 1 |
| Pan, S | 1 |
| Thirumalareddy, AR | 1 |
| Konakanchi, VC | 1 |
| Boina, K | 1 |
| Suggu, S | 1 |
| Shirzadi, M | 1 |
| Saunes, M | 1 |
| Reimers, A | 1 |
| Brodtkorb, E | 1 |
| Jang, Y | 1 |
| Moon, J | 1 |
| Kim, N | 1 |
| Kim, TJ | 1 |
| Jun, JS | 1 |
| Shin, YW | 1 |
| Chang, H | 1 |
| Kang, HR | 1 |
| Lee, ST | 1 |
| Jung, KH | 1 |
| Park, KI | 1 |
| Jung, KY | 1 |
| Chu, K | 1 |
| Lee, SK | 2 |
| Kverno, K | 1 |
| Beauvois, L | 1 |
| Dudley-Brown, S | 1 |
| Iriki, H | 1 |
| Ouchi, T | 1 |
| Ito, H | 1 |
| Sawada, M | 1 |
| Mukai, M | 1 |
| Nomura, H | 1 |
| Baba, Y | 1 |
| Adachi, T | 1 |
| Funakoshi, T | 1 |
| Amagai, M | 1 |
| Takahashi, H | 1 |
| Inaba, T | 1 |
| Sogawa, R | 1 |
| Mizoguchi, Y | 1 |
| Tateishi, H | 1 |
| Kunitake, Y | 1 |
| Kato, TA | 1 |
| Monji, A | 1 |
| Hosohata, K | 1 |
| Inada, A | 1 |
| Oyama, S | 1 |
| Niinomi, I | 1 |
| Wakabayashi, T | 1 |
| Iwanaga, K | 1 |
| Atanasković-Marković, M | 1 |
| Janković, J | 1 |
| Tmušić, V | 1 |
| Gavrović-Jankulović, M | 1 |
| Ćirković Veličković, T | 1 |
| Nikolić, D | 1 |
| Škorić, D | 1 |
| Park, SP | 1 |
| Kakisaka, Y | 1 |
| Jin, K | 1 |
| Kato, K | 1 |
| Iwasaki, M | 1 |
| Nakasato, N | 1 |
| Wang, XQ | 2 |
| Xiong, J | 1 |
| Xu, WH | 1 |
| Yu, SY | 1 |
| Huang, XS | 1 |
| Zhang, JT | 1 |
| Tian, CL | 1 |
| Huang, DH | 1 |
| Jia, WQ | 1 |
| Lang, SY | 2 |
| Nathan, K | 1 |
| Agarwal, A | 1 |
| Gable, B | 1 |
| McFarland, M | 1 |
| Egunsola, O | 1 |
| Choonara, I | 1 |
| Sammons, HM | 1 |
| Provenzani, A | 1 |
| Labbozzetta, M | 1 |
| Notarbartolo, M | 1 |
| Poma, P | 1 |
| Polidori, P | 1 |
| Vizzini, G | 1 |
| D'Alessandro, N | 1 |
| Jang, HW | 1 |
| Kim, SW | 1 |
| Cho, YJ | 1 |
| Heo, K | 1 |
| Lee, BI | 1 |
| Jang, IJ | 1 |
| Lee, MG | 1 |
| Kim, WJ | 1 |
| Lee, JH | 1 |
| Ozisik, L | 1 |
| Tanriover, MD | 1 |
| Saka, E | 1 |
| Lorberg, B | 1 |
| Youssef, NA | 1 |
| Bhagwagar, Z | 2 |
| Serati Shirazi, Z | 1 |
| Inaloo, S | 1 |
| Joe, SH | 1 |
| Chang, JS | 1 |
| Won, S | 1 |
| Rim, HD | 1 |
| Ha, TH | 1 |
| Ha, K | 1 |
| Ferguson, LP | 1 |
| Dargan, PI | 1 |
| Hood, JL | 1 |
| Tibby, SM | 1 |
| Woo, YS | 1 |
| Bahk, WM | 1 |
| Jon, DI | 1 |
| Joo, YH | 1 |
| Kim, W | 1 |
| Seo, JS | 1 |
| Ahn, YM | 1 |
| Chung, SK | 1 |
| Won, SH | 1 |
| Shin, YC | 1 |
| Yoon, BH | 1 |
| Jung, SH | 1 |
| Seok, JH | 1 |
| Lee, YS | 1 |
| Kim, Y | 1 |
| Min, KJ | 1 |
| Pae, CU | 1 |
| Egger, C | 1 |
| Muehlbacher, M | 1 |
| Grohmann, R | 1 |
| Stuppaeck, C | 1 |
| Shi, XB | 1 |
| Tian, HJ | 1 |
| Wang, RF | 1 |
| Yang, F | 1 |
| Roquin, G | 1 |
| Peres, M | 1 |
| Lerolle, N | 1 |
| Dib, N | 1 |
| Mercat, A | 1 |
| Croue, A | 1 |
| Augusto, JF | 1 |
| Tjia-Leong, E | 1 |
| Leong, K | 1 |
| Pereira de Silva, N | 1 |
| Piquioni, P | 1 |
| Kochen, S | 1 |
| Saidon, P | 1 |
| Mills, JK | 1 |
| Lewis, TG | 1 |
| Mughal, K | 1 |
| Ali, I | 1 |
| Ugur, A | 1 |
| Whitehouse, WP | 1 |
| Moosbrugger, EA | 1 |
| Adams, BB | 1 |
| Yang, CY | 1 |
| Dao, RL | 1 |
| Lee, TJ | 1 |
| Lu, CW | 1 |
| Yang, CH | 1 |
| Hung, SI | 1 |
| Chung, WH | 1 |
| Alkhotani, A | 1 |
| McLachlan, RS | 1 |
| Monzón, S | 1 |
| Garcés, MM | 1 |
| Reichelt, C | 1 |
| Lezaun, A | 1 |
| Colás, C | 1 |
| Singh, J | 1 |
| Zarate, CA | 1 |
| Krystal, AD | 1 |
| Manfredi, G | 1 |
| Pacchiarotti, I | 1 |
| Kotzalidis, GD | 1 |
| Ruberto, A | 1 |
| Girardi, P | 1 |
| Tatarelli, R | 1 |
| Zidd, AG | 1 |
| Hack, JB | 1 |
| P-Codrea Tigaran, S | 1 |
| Sidenius, P | 1 |
| Dam, M | 1 |
| Rahman, M | 1 |
| Haider, N | 1 |
| Ketter, TA | 2 |
| Wang, PW | 1 |
| Chandler, RA | 1 |
| Alarcon, AM | 1 |
| Becker, OV | 1 |
| Nowakowska, C | 1 |
| O'Keeffe, CM | 1 |
| Schumacher, MR | 1 |
| Goodwin, GM | 1 |
| Hirsch, LJ | 1 |
| Weintraub, DB | 1 |
| Buchsbaum, R | 1 |
| Spencer, HT | 1 |
| Straka, T | 1 |
| Hager, M | 1 |
| Resor, SR | 1 |
| Greist, JH | 1 |
| Graham, JA | 1 |
| Roberts, JN | 1 |
| Thompson, TR | 1 |
| Nanry, KP | 1 |
| Devulder, J | 1 |
| Biton, V | 1 |
| Hussain, N | 1 |
| Gosalakkal, JA | 1 |
| Sabroe, TP | 1 |
| Sabers, A | 1 |
| Pellock, JM | 1 |
| Messenheimer, J | 2 |
| Mullens, EL | 1 |
| Giorgi, L | 1 |
| Young, F | 1 |
| Mackay, FJ | 1 |
| Wilton, LV | 1 |
| Pearce, GL | 1 |
| Freemantle, SN | 1 |
| Mann, RD | 1 |
| Tugendhaft, P | 1 |
| Simonart, T | 1 |
| Gilliam, F | 1 |
| Vazquez, B | 1 |
| Sackellares, JC | 1 |
| Chang, GY | 1 |
| Nyberg, J | 1 |
| Risner, ME | 1 |
| Rudd, GD | 1 |
| Wong, IC | 1 |
| Mawer, GE | 1 |
| Sander, JW | 1 |
| Messenheimer, JA | 1 |
| Guberman, AH | 1 |
| Simpson, DM | 1 |
| Olney, R | 1 |
| McArthur, JC | 1 |
| Khan, A | 1 |
| Godbold, J | 1 |
| Ebel-Frommer, K | 1 |
| Besag, FM | 1 |
| Ng, GY | 1 |
| Pool, F | 1 |
| Wensween, CA | 1 |
| Bouwes Bavinck, JN | 1 |
| Hurley, SC | 1 |
| Anderson, GD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Protocol Establishment for the Prevention of Lamotrigine-induced Skin Rash in Epilepsy Patients: A Pilot Study[NCT03220256] | Phase 2 | 30 participants (Anticipated) | Interventional | 2016-08-02 | Recruiting | ||
| A Multi-centre, Observational Study to Evaluate the Incidence of Non-serious Rash in Korean Bipolar I Patients With Lamotrigine Therapy in Real World Setting[NCT00460226] | 238 participants (Actual) | Observational | 2007-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
11 reviews available for lamotrigine and Exanthem
| Article | Year |
|---|---|
Lamotrigine add-on therapy for drug-resistant generalised tonic-clonic seizures.
Topics: Anticonvulsants; Chemotherapy, Adjuvant; Dizziness; Drug Eruptions; Drug Resistant Epilepsy; Epileps | 2020 |
Risk of a lamotrigine-related skin rash: current meta-analysis and postmarketing cohort analysis.
Topics: Anticonvulsants; Drug Eruptions; Exanthema; Humans; Incidence; Lamotrigine; Randomized Controlled Tr | 2015 |
Safety of lamotrigine in paediatrics: a systematic review.
Topics: Abdominal Pain; Anticonvulsants; Child; Dizziness; Drug Therapy, Combination; Exanthema; Headache; H | 2015 |
Lamotrigine-associated rash: to rechallenge or not to rechallenge?
Topics: Anticonvulsants; Bipolar Disorder; Databases, Bibliographic; Dose-Response Relationship, Drug; Drug | 2009 |
Lamotrigine adjunctive therapy for refractory generalized tonic-clonic seizures.
Topics: Anticonvulsants; Chemotherapy, Adjuvant; Drug Eruptions; Epilepsy, Tonic-Clonic; Exanthema; Humans; | 2010 |
Lamotrigine in the treatment of bipolar disorder.
Topics: Bipolar Disorder; Exanthema; Humans; Lamotrigine; Triazines | 2005 |
Pharmacokinetics, toxicology and safety of lamotrigine in epilepsy.
Topics: Anticonvulsants; Dose-Response Relationship, Drug; Epilepsy; Exanthema; Humans; Intestinal Absorptio | 2006 |
Overview of lamotrigine and the new antiepileptic drugs: the challenge.
Topics: Acetates; Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Drug Interactions; Epilepsy; | 1997 |
Safety review of adult clinical trial experience with lamotrigine.
Topics: Adolescent; Adult; Anticonvulsants; Calcium Channel Blockers; Drug Therapy, Combination; Exanthema; | 1998 |
Lamotrigine update and its use in mood disorders.
Topics: Acetates; Aggression; Amines; Antidepressive Agents; Bipolar Disorder; Cyclohexanecarboxylic Acids; | 2002 |
Children versus adults: pharmacokinetic and adverse-effect differences.
Topics: Adolescent; Age Factors; Anticonvulsants; Chemical and Drug Induced Liver Injury; Child; Child, Pres | 2002 |
5 trials available for lamotrigine and Exanthem
| Article | Year |
|---|---|
Rash in adult patients receiving lamotrigine to treat bipolar I disorder in Korea: a multicenter, prospective, naturalistic, open-label trial.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Exanthema; Female; Humans; Incidence; Korea; Lamotrigine; | 2009 |
Dermatology precautions and slower titration yield low incidence of lamotrigine treatment-emergent rash.
Topics: Adult; Ambulatory Care; Anticonvulsants; Bipolar Disorder; Cohort Studies; Drug Administration Sched | 2005 |
The effect of dermatologic precautions on the incidence of rash with addition of lamotrigine in the treatment of bipolar I disorder: a randomized trial.
Topics: Adolescent; Adult; Ambulatory Care; Antipsychotic Agents; Bipolar Disorder; Cohort Studies; Comorbid | 2006 |
An active-control trial of lamotrigine monotherapy for partial seizures.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Carbamazepine; Double-Blind Method; Epilepsies, Partial; E | 1998 |
A placebo-controlled trial of lamotrigine for painful HIV-associated neuropathy.
Topics: Adult; Analgesics; Analysis of Variance; Double-Blind Method; Drug Eruptions; Exanthema; Female; HIV | 2000 |
50 other studies available for lamotrigine and Exanthem
| Article | Year |
|---|---|
Acute onset of fever, eosinophilia, rash, acute kidney injury, and a positive Monospot test in a patient on lamotrigine: DRESS syndrome.
Topics: Acute Kidney Injury; Anticonvulsants; Drug Hypersensitivity Syndrome; Eosinophilia; Exanthema; Fever | 2022 |
Analysis of adverse drug events in patients with bipolar disorders using the Japanese Adverse Drug Event Report database.
Topics: Adverse Drug Reaction Reporting Systems; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Drug | 2022 |
DRUG-INDUCED HYPERSENSITIVITY SYNDROME CAUSED BY LAMOTRIGINE, A CASE REPORT.
Topics: Anticonvulsants; Drug Hypersensitivity Syndrome; Eosinophilia; Exanthema; Female; Humans; Lamotrigin | 2022 |
Potential Involvement of Sulfotransferase in the Mechanism of Lamotrigine-induced Skin Rash.
Topics: Drug Eruptions; Exanthema; Humans; Lamotrigine; Nevirapine; Oxides; Sertraline; Sulfates; Sulfotrans | 2023 |
Use of clozapine for resolving lamotrigine-induced skin lesions caused by schizophrenia treatment.
Topics: Adult; Antipsychotic Agents; Clozapine; Exanthema; Female; Humans; Lamotrigine; Schizophrenia | 2019 |
A High Plasma Lamotrigine Concentration at Week 2 as a Risk Factor for Lamotrigine-Related Rash.
Topics: Antipsychotic Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Exanthem | 2020 |
Slower titration of lamotrigine reduces the risk of rash.
Topics: Age Factors; Cross-Sectional Studies; Drug Administration Schedule; Exanthema; Humans; Lamotrigine; | 2020 |
Comparison of long-term efficacy, tolerability, and safety of oxcarbazepine, lamotrigine, and levetiracetam in patients with newly diagnosed focal epilepsy: An observational study in the real world.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Child, Preschool; Cohort Studies; Dizziness; Drug A | 2020 |
Acute localised exanthematous pustulosis (ALEP) over penis secondary to lamotrigine.
Topics: Acute Generalized Exanthematous Pustulosis; Anticonvulsants; Exanthema; Humans; Lamotrigine; Male; P | 2022 |
Rash during lamotrigine treatment is not always drug hypersensitivity: A retrospective cohort study among children and adults.
Topics: Adult; Anticonvulsants; Child; Drug Hypersensitivity; Exanthema; Humans; Lamotrigine; Retrospective | 2021 |
A new rapid titration protocol for lamotrigine that reduces the risk of skin rash.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Epilepsy; Exanthema; Humans; Lamotrigin | 2021 |
Lamotrigine rash: Benign allergy or severe adverse reaction?
Topics: Adult; Anticonvulsants; Exanthema; Female; Humans; Hypersensitivity; Lamotrigine; Severity of Illnes | 2018 |
Case of lamotrigine-induced drug adverse reaction under tocilizumab treatment with clinical and virological features of drug-induced hypersensitivity syndrome.
Topics: Adult; Antibodies, Monoclonal, Humanized; Anticonvulsants; Arthritis, Rheumatoid; Biopsy; C-Reactive | 2018 |
Lamotrigine Rechallenge in Treatment-Resistant Bipolar Disorder.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Antimanic Agents; Bipolar Disorder; Che | 2018 |
Adverse Cutaneous Drug Reactions Associated with Old- and New- Generation Antiepileptic Drugs Using the Japanese Pharmacovigilance Database.
Topics: Anticonvulsants; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Exanthema; Fem | 2019 |
Hypersensitivity reactions to antiepileptic drugs in children.
Topics: Adolescent; Allergens; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Diagnosis, Different | 2019 |
Depression in patients with newly diagnosed epilepsy predicts lamotrigine-induced rash: a short-term observational study.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Depression; Epilepsy; Exanthema; Female; Humans; Lamotrigi | 2013 |
Seizure freedom after lamotrigine rash: a peculiar phenomenon in epilepsy.
Topics: Anticonvulsants; Drug Eruptions; Epilepsy, Frontal Lobe; Exanthema; Female; Humans; Lamotrigine; Mid | 2014 |
Lamotrigine-induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).
Topics: Anticonvulsants; Drug Hypersensitivity Syndrome; Eosinophils; Exanthema; Female; Fever; Humans; Lamo | 2015 |
Rash and multiorgan dysfunction following lamotrigine: could genetic be involved?
Topics: Anticonvulsants; Exanthema; Female; Genotype; Glucuronosyltransferase; Humans; Lamotrigine; Multiple | 2015 |
GWAS identifies two susceptibility loci for lamotrigine-induced skin rash in patients with epilepsy.
Topics: Anticonvulsants; Asian People; Cohort Studies; Drug Eruptions; Epilepsy; Exanthema; Genetic Predispo | 2015 |
Autoimmune Limbic Encephalitis and Syndrome of Inappropriate Antidiuretic Hormone Secretion Associated with Lamotrigine-induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) Syndrome.
Topics: Adult; Anticonvulsants; Autoimmune Diseases; Drug Hypersensitivity; Eosinophilia; Exanthema; Female; | 2016 |
Intravenous immunoglobulin in the treatment of lamotrigine- induced toxic epidermal necrolysis.
Topics: Blister; Child; Exanthema; Female; Fever; Humans; Immunoglobulins, Intravenous; Lamotrigine; Seizure | 2008 |
Feasibility of a slower lamotrigine titration schedule for bipolar depression: a naturalistic study.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Dr | 2009 |
Life-threatening organ failure after lamotrigine therapy.
Topics: Anticonvulsants; Child; Contraindications; Drug Therapy, Combination; Exanthema; Female; Fever; Huma | 2009 |
Rash and lamotrigine in bipolar patients.
Topics: Antimanic Agents; Bipolar Disorder; Exanthema; Humans; Lamotrigine; Randomized Controlled Trials as | 2010 |
Clozapine intoxication in a patient with lamotrigine-induced rash.
Topics: Analgesics; Antipsychotic Agents; Bipolar Disorder; Clozapine; Exanthema; Humans; Lamotrigine; Male; | 2010 |
Cross-reactivity of skin rashes with current antiepileptic drugs in Chinese population.
Topics: Adolescent; Adult; Aged; Amines; Anticonvulsants; Carbamazepine; Chi-Square Distribution; Child; Chi | 2010 |
First report of lamotrigine-induced drug rash with eosinophilia and systemic symptoms syndrome with pancreatitis.
Topics: Aged; Drug Eruptions; Eosinophilia; Exanthema; Humans; Lamotrigine; Male; Pancreatitis; Syndrome; Tr | 2010 |
Risk factors associated with DRESS syndrome produced by aromatic and non-aromatic antipiletic drugs.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Anticonvulsants; Carbamazepine; Disease Susceptibility; | 2011 |
Retention rate of clobazam, topiramate and lamotrigine in children with intractable epilepsies at 1 year.
Topics: Adolescent; Benzodiazepines; Child; Child, Preschool; Clobazam; Epilepsy; Exanthema; Female; Fructos | 2011 |
Disseminated eruption of ectopic sebaceous glands following Stevens-Johnson syndrome.
Topics: Adolescent; Biopsy, Needle; Exanthema; Facial Dermatoses; Female; Follow-Up Studies; Humans; Immunoh | 2011 |
Severe cutaneous adverse reactions to antiepileptic drugs in Asians.
Topics: Adult; Anticonvulsants; Asian People; Carbamazepine; Exanthema; Female; Follow-Up Studies; Humans; L | 2011 |
Levetiracetam induced angioedema in a patient with previous anticonvulsant hypersensitivity reaction to phenytoin and lamotrigine.
Topics: Adult; Angioedema; Anticonvulsants; Exanthema; Female; Humans; Lamotrigine; Levetiracetam; Phenytoin | 2012 |
Positive patch test in hypersensitivity to lamotrigine.
Topics: Aged; Anticonvulsants; Exanthema; Humans; Lamotrigine; Male; Patch Tests; Triazines | 2002 |
Case report: Successful riluzole augmentation therapy in treatment-resistant bipolar depression following the development of rash with lamotrigine.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Drug Synergism; Exanthema; Excitatory Amino Acid Ant | 2004 |
Successful rechallenge with slowly titrated lamotrigine after rash.
Topics: Antimanic Agents; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Dose-Resp | 2004 |
Pediatric ingestion of lamotrigine.
Topics: Anticonvulsants; Consciousness Disorders; Exanthema; Female; Humans; Infant; Lamotrigine; Liver; Tri | 2004 |
Lamotrigine-induced rash--worth a rechallenge.
Topics: Anticonvulsants; Epilepsy, Generalized; Exanthema; Humans; Lamotrigine; Retrospective Studies; Risk | 2005 |
Anticonvulsant hypersensitivity syndrome from addition of lamotrigine to divalproex.
Topics: Anticonvulsants; Bipolar Disorder; Drug Hypersensitivity; Drug Therapy, Combination; Exanthema; Fema | 2005 |
Predictors of Lamotrigine-associated rash.
Topics: Adolescent; Adult; Age Factors; Ambulatory Care; Anticonvulsants; Child; Drug Administration Schedul | 2006 |
The relevance of monitoring lamotrigine serum concentrations in chronic pain patients.
Topics: Administration, Oral; Adult; Analgesics; Chronic Disease; Cytochrome P-450 Enzyme System; Dose-Respo | 2006 |
Lamotrigine rash--a potentially life-threatening complication.
Topics: Anticonvulsants; Child; Epilepsy; Exanthema; Humans; Lamotrigine; Male; Physical Examination; Triazi | 2007 |
Progressive anticonvulsant hypersensitivity syndrome associated with change of drug product.
Topics: Adult; Anticonvulsants; Arthralgia; Arthritis; Drugs, Generic; Epilepsy; Exanthema; Fever; Humans; L | 2008 |
Safety of long-term lamotrigine in epilepsy.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Age Factors; Aged; Anticonvulsants; Chil | 1997 |
Phenytoin-like hypersensitivity associated with lamotrigine.
Topics: Anticonvulsants; Dose-Response Relationship, Drug; Drug Eruptions; Exanthema; Humans; Lamotrigine; P | 1998 |
Factors influencing the incidence of lamotrigine-related skin rash.
Topics: Adolescent; Adult; Anticonvulsants; Child; Dose-Response Relationship, Drug; Drug Therapy, Combinati | 1999 |
Rash with lamotrigine: dosing guidelines.
Topics: Age Factors; Anticonvulsants; Child; Child, Preschool; Epilepsy; Exanthema; Humans; Lamotrigine; Pra | 2000 |
Successful re-introduction of lamotrigine after initial rash.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Adminis | 2000 |
[Overlapping acute disseminated exanthematous pustulosis and toxic epidermal necrolysis].
Topics: Acute Disease; Adult; Anticonvulsants; Diagnosis, Differential; Exanthema; Female; Fever; Humans; La | 2001 |